藤居勇貴 院生の論文が Invest New Drugs 誌に掲載されました。
2021/05/07
お知らせ
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.
Fujii Y, Kamachi H, Matsuzawa F, Mizukami T, Kobayashi N, Fukai M, Taketomi A.
Invest New Drugs. 2021 Apr 27. doi: 10.1007/s10637-021-01118-1.